The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

doi:10.1007/s13311-020-00907-5

Editorial

. 2020 Jul;17(3):968-970.

doi: 10.1007/s13311-020-00907-5.

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

Carolyn H Goldschmidt¹, Jeffrey A Cohen²

Affiliations

¹ Mellen Center U-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA.
² Mellen Center U-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA. cohenj@ccf.org.

PMID: 32761325
PMCID: PMC7609671
DOI: 10.1007/s13311-020-00907-5

Editorial

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

Carolyn H Goldschmidt et al. Neurotherapeutics. 2020 Jul.

. 2020 Jul;17(3):968-970.

doi: 10.1007/s13311-020-00907-5.

Authors

Carolyn H Goldschmidt¹, Jeffrey A Cohen²

Affiliations

¹ Mellen Center U-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA.
² Mellen Center U-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA. cohenj@ccf.org.

PMID: 32761325
PMCID: PMC7609671
DOI: 10.1007/s13311-020-00907-5

No abstract available

Keywords: Biotin; MS relapse; multiple sclerosis; progressive MS.

PubMed Disclaimer

Comment on

Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort.
Branger P, Parienti JJ, Derache N, Kassis N, Assouad R, Maillart E, Defer G. Branger P, et al. Neurotherapeutics. 2020 Jul;17(3):989-993. doi: 10.1007/s13311-020-00880-z. Neurotherapeutics. 2020. PMID: 32557122 Free PMC article.

Cited by

Macronutrients, vitamins and minerals in the diet of multiple sclerosis patients.
Zielińska M, Michońska I. Zielińska M, et al. Postep Psychiatr Neurol. 2022 Sep;31(3):128-137. doi: 10.5114/ppn.2022.121730. Epub 2022 Nov 29. Postep Psychiatr Neurol. 2022. PMID: 37082222 Free PMC article. Review.
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.
Kamma E, Lasisi W, Libner C, Ng HS, Plemel JR. Kamma E, et al. J Neuroinflammation. 2022 Feb 10;19(1):45. doi: 10.1186/s12974-022-02408-y. J Neuroinflammation. 2022. PMID: 35144628 Free PMC article. Review.
Hormone Immunoassay Interference: A 2021 Update.
Ghazal K, Brabant S, Prie D, Piketty ML. Ghazal K, et al. Ann Lab Med. 2022 Jan 1;42(1):3-23. doi: 10.3343/alm.2022.42.1.3. Ann Lab Med. 2022. PMID: 34374345 Free PMC article. Review.
New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration.
Podbielska M, O'Keeffe J, Pokryszko-Dragan A. Podbielska M, et al. Int J Mol Sci. 2021 Jul 7;22(14):7319. doi: 10.3390/ijms22147319. Int J Mol Sci. 2021. PMID: 34298940 Free PMC article. Review.

References

1. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–20. doi: 10.1056/NEJMoa1606468. - DOI - PubMed
1. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. doi: 10.1016/S0140-6736(18)30475-6. - DOI - PubMed
1. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–31. doi: 10.1177/1352458516667568. - DOI - PMC - PubMed
1. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–69. doi: 10.1016/j.msard.2015.01.005. - DOI - PubMed
1. Siddiqui U, Egnor E, Sloane JA. Biotin supplementation in MS clinically valuable but can alter multiple blood test results. Mult Scler. 2017;23(4):619–20. doi: 10.1177/1352458516680751. - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–20. doi: 10.1056/NEJMoa1606468. - DOI - PubMed

[2] Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–20. doi: 10.1056/NEJMoa1606468. - DOI - PubMed

[3] Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. doi: 10.1016/S0140-6736(18)30475-6. - DOI - PubMed

[4] Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. doi: 10.1016/S0140-6736(18)30475-6. - DOI - PubMed

[5] Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–31. doi: 10.1177/1352458516667568. - DOI - PMC - PubMed

[6] Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–31. doi: 10.1177/1352458516667568. - DOI - PMC - PubMed

[7] Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–69. doi: 10.1016/j.msard.2015.01.005. - DOI - PubMed

[8] Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–69. doi: 10.1016/j.msard.2015.01.005. - DOI - PubMed

[9] Siddiqui U, Egnor E, Sloane JA. Biotin supplementation in MS clinically valuable but can alter multiple blood test results. Mult Scler. 2017;23(4):619–20. doi: 10.1177/1352458516680751. - DOI - PubMed

[10] Siddiqui U, Egnor E, Sloane JA. Biotin supplementation in MS clinically valuable but can alter multiple blood test results. Mult Scler. 2017;23(4):619–20. doi: 10.1177/1352458516680751. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

Affiliations

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical